Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 115


Regression from pre-diabetes to normal glucose regulation in the diabetes prevention program.

Perreault L, Kahn SE, Christophi CA, Knowler WC, Hamman RF; Diabetes Prevention Program Research Group..

Diabetes Care. 2009 Sep;32(9):1583-8. doi: 10.2337/dc09-0523. Epub 2009 Jul 8.


Effect of regression from prediabetes to normal glucose regulation on long-term reduction in diabetes risk: results from the Diabetes Prevention Program Outcomes Study.

Perreault L, Pan Q, Mather KJ, Watson KE, Hamman RF, Kahn SE; Diabetes Prevention Program Research Group..

Lancet. 2012 Jun 16;379(9833):2243-51. doi: 10.1016/S0140-6736(12)60525-X. Epub 2012 Jun 9.


Lifestyle and metformin treatment favorably influence lipoprotein subfraction distribution in the Diabetes Prevention Program.

Goldberg R, Temprosa M, Otvos J, Brunzell J, Marcovina S, Mather K, Arakaki R, Watson K, Horton E, Barrett-Connor E.

J Clin Endocrinol Metab. 2013 Oct;98(10):3989-98. doi: 10.1210/jc.2013-1452. Epub 2013 Aug 26.


The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes.

Diabetes Prevention Program Research Group., Crandall J, Schade D, Ma Y, Fujimoto WY, Barrett-Connor E, Fowler S, Dagogo-Jack S, Andres R.

J Gerontol A Biol Sci Med Sci. 2006 Oct;61(10):1075-81.


Alcohol consumption and diabetes risk in the Diabetes Prevention Program.

Crandall JP, Polsky S, Howard AA, Perreault L, Bray GA, Barrett-Connor E, Brown-Friday J, Whittington T, Foo S, Ma Y, Edelstein SL; Diabetes Prevention Program Research Group..

Am J Clin Nutr. 2009 Sep;90(3):595-601. doi: 10.3945/ajcn.2008.27382. Epub 2009 Jul 29.


Role of insulin secretion and sensitivity in the evolution of type 2 diabetes in the diabetes prevention program: effects of lifestyle intervention and metformin.

Kitabchi AE, Temprosa M, Knowler WC, Kahn SE, Fowler SE, Haffner SM, Andres R, Saudek C, Edelstein SL, Arakaki R, Murphy MB, Shamoon H; Diabetes Prevention Program Research Group..

Diabetes. 2005 Aug;54(8):2404-14.


Sex differences in diabetes risk and the effect of intensive lifestyle modification in the Diabetes Prevention Program.

Perreault L, Ma Y, Dagogo-Jack S, Horton E, Marrero D, Crandall J, Barrett-Connor E; Diabetes Prevention Program..

Diabetes Care. 2008 Jul;31(7):1416-21. doi: 10.2337/dc07-2390. Epub 2008 Mar 20.


Effect of progression from impaired glucose tolerance to diabetes on cardiovascular risk factors and its amelioration by lifestyle and metformin intervention: the Diabetes Prevention Program randomized trial by the Diabetes Prevention Program Research Group.

Goldberg RB, Temprosa M, Haffner S, Orchard TJ, Ratner RE, Fowler SE, Mather K, Marcovina S, Saudek C, Matulik MJ, Price D; Diabetes Prevention Program Research Group..

Diabetes Care. 2009 Apr;32(4):726-32. doi: 10.2337/dc08-0494. Epub 2009 Jan 26.


[Progress in the prevention of type 2 diabetes].

Schernthaner G.

Wien Klin Wochenschr. 2003 Nov 28;115(21-22):745-57. Review. German.


Metabolic syndrome components and their response to lifestyle and metformin interventions are associated with differences in diabetes risk in persons with impaired glucose tolerance.

Florez H, Temprosa MG, Orchard TJ, Mather KJ, Marcovina SM, Barrett-Connor E, Horton E, Saudek C, Pi-Sunyer XF, Ratner RE, Goldberg RB; Diabetes Prevention Program Research Group..

Diabetes Obes Metab. 2014 Apr;16(4):326-33. doi: 10.1111/dom.12220. Epub 2013 Oct 29.


Change in adiponectin explains most of the change in HDL particles induced by lifestyle intervention but not metformin treatment in the Diabetes Prevention Program.

Goldberg RB, Temprosa M, Mele L, Orchard T, Mather K, Bray G, Horton E, Kitabchi A, Krakoff J, Marcovina S, Perreault L, White N; Diabetes Prevention Program Research Group..

Metabolism. 2016 May;65(5):764-75. doi: 10.1016/j.metabol.2015.11.011. Epub 2015 Dec 2.


Long-term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study.

Diabetes Prevention Program Research Group..

Diabetes Care. 2012 Apr;35(4):731-7. doi: 10.2337/dc11-1299.


A pilot study to examine the feasibility of insulin glargine in subjects with impaired fasting glucose, impaired glucose tolerance or new-onset type 2 diabetes.

Marbury TC, Schwartz S, Rosenberg MA, Jariwala N, Becker RH, Johnston PS.

Exp Clin Endocrinol Diabetes. 2008 May;116(5):282-8. doi: 10.1055/s-2007-1022521.


Early response to preventive strategies in the Diabetes Prevention Program.

Maruthur NM, Ma Y, Delahanty LM, Nelson JA, Aroda V, White NH, Marrero D, Brancati FL, Clark JM; Diabetes Prevention Program Research Group..

J Gen Intern Med. 2013 Dec;28(12):1629-36. doi: 10.1007/s11606-013-2548-4. Epub 2013 Jul 17.


Successful treatment of prediabetes in clinical practice: targeting insulin resistance and β-cell dysfunction.

Armato J, DeFronzo RA, Abdul-Ghani M, Ruby R.

Endocr Pract. 2012 May-Jun;18(3):342-50. doi: 10.4158/EP11194.OR.


The rationale, design, and baseline characteristics of PREVENT-DM: A community-based comparative effectiveness trial of lifestyle intervention and metformin among Latinas with prediabetes.

Perez A, Alos VA, Scanlan A, Maia CM, Davey A, Whitaker RC, Foster GD, Ackermann RT, O'Brien MJ.

Contemp Clin Trials. 2015 Nov;45(Pt B):320-7. doi: 10.1016/j.cct.2015.10.011. Epub 2015 Oct 24.


HbA1c as a predictor of diabetes and as an outcome in the diabetes prevention program: a randomized clinical trial.

Diabetes Prevention Program Research Group..

Diabetes Care. 2015 Jan;38(1):51-8. doi: 10.2337/dc14-0886. Epub 2014 Oct 21.


Effect of anti-IL-1β antibody (canakinumab) on insulin secretion rates in impaired glucose tolerance or type 2 diabetes: results of a randomized, placebo-controlled trial.

Rissanen A, Howard CP, Botha J, Thuren T; Global Investigators..

Diabetes Obes Metab. 2012 Dec;14(12):1088-96. doi: 10.1111/j.1463-1326.2012.01637.x. Epub 2012 Jul 19.


Supplemental Content

Support Center